psoriatic arthritis
Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
June 13, 2025Medical Communications, Research and Development European Alliance of Associations for Rheumatology, Rheumatology, bristol myers squibb, clinical trial, psoriatic arthritis
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, showing that Sotyktu (deucravacitinib) significantly …
Abbvie psoriatic arthritis drug approved for use in Scotland
May 11, 2021Manufacturing and Production AbbVie, NHS, arthritis, psoriatic arthritis
Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in …
Janssen’s Tremfya shows skin clearance benefit for psoriatic arthritis patients in two Phase 3 studies
June 4, 2020Research and Development Janssen, Tremfya, psoriatic arthritis
Janssen has revealed data from two Phase 3 trials for Tremfya (guselkumab), showing improvement in skin clearance and symptoms in …
AbbVie’s Rinvoq hits target in psoriatic arthritis sub-population at Phase 3
February 6, 2020Research and Development AbbVie, Rinvoq, pharma, psoriatic arthritis
AbbVie has unveiled new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq (upadacitinib) in the treatment of …
Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows
October 10, 2019Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis
Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …
NICE recommends Eli Lilly’s psoriatic arthritis drug
August 9, 2018Research and Development, Sales and Marketing Eli Lilly, England, NICE, Wales, psoriatic arthritis
Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option …
Pfizer’s Xeljanz scores EU approval for active psoriatic arthritis
June 29, 2018Medical Communications, Sales and Marketing EU, Europe, Pfizer, Xeljanz, pharma, psoriatic arthritis
Pfizer has announced that the European Commission (EC) has approved Xeljanz in combination with methotrexate (MTX) for the treatment of …
Eli Lilly’s Taltz get EU approval in psoriatic arthritis subgroup
January 24, 2018Research and Development, Sales and Marketing EU, Eli Lilly, Europe, European Commission, Taltz, pharma, psoriatic arthritis
Eli Lilly has revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been awarded marketing approval from the European Commission …
FDA approves Pfizer’s Xeljanz for psoriatic arthritis
December 18, 2017Sales and Marketing FDA, Pfizer, Xeljanz, pharma, psoriatic arthritis
Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis …
Celgene’s Otezla hits primary endpoint in psoriatic arthritis study
November 15, 2016Manufacturing and Production, Research and Development Celgene, otezla, psoriatic arthritis
Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment …
Novartis reveals positive three-year efficacy data for psoriatic arthritis drug
November 15, 2016Manufacturing and Production, Research and Development Cosentyx, Novartis, psoriatic arthritis
Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate …
Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib
Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs
December 16, 2015Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin
NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …
Novartis’ Cosentyx gets European approval for two conditions
October 23, 2015Medical Communications, Sales and Marketing Cosentyx, European Medicines Agency, Novartis, psoriatic arthritis
The scientific committee of the European Medicines Agency (EMA) has recommended the approval of Novartis’ Cosentyx (secukinumab) for treatment of ankylosing …
AbbVie highlights treatment adherence
June 12, 2014Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis
Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
